Recently, one of the ketone bodies, β-hydroxybutyrate, was shown to specifically inhibit NLRP3 inflammasome [27] and synthetic compound MCC950 demonstrated effective and specific NLRP3 inflammasome inhibition with promising results in the mouse model of CAPS [28]. This evidence concerns the gene NLRP3 and cryopyrin-associated periodic syndrome.